Published in European journal of neurology
The objective of this study was to assess the neurological manifestations in a series of consecutive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive patients, comparing their frequency with a population hospitalized in the same period for flu/respiratory symptoms, finally not related to SARS-CoV-2. Patients with flu/respirator...
Published in European journal of neurology
Dementia is one of the most common disorders and is associated with increased morbidity, mortality and decreased quality of life. The present guideline addresses important medical management issues including systematic medical follow-up, vascular risk factors in dementia, pain in dementia, use of antipsychotics in dementia and epilepsy in dementia....
Published in European journal of neurology
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting primarily the motor system, but in which extra-motor manifestations are increasingly recognized. The loss of upper and lower motor neurons in the motor cortex, the brain stem nuclei and the anterior horn of the spinal cord gives rise to progressive muscle weakness and was...
Published in European Journal of Neurology
Background Since the outbreak of the SARS‐CoV‐2 pandemic several reports indicated neurological involvement in COVID‐19 disease. Muscle involvement has also been reported as evidenced by creatine kinase (CK) elevations and reports of myalgia. Methods CK, markers of inflammation, pre‐existing diseases and statin use were extracted from records of Au...
Published in European Journal of Neurology
A 20‐year‐old male, with no relevant previous medical history, was admitted due to bilateral facial weakness. Two weeks before, he noticed odynophagia and fever of 39ºC without cough. He associated significant asthenia with headache, myalgia, nausea, and vomiting and he was treated with levofloxacin 500mg qd for 7 days. One week after, during an in...
Published in European Journal of Neurology
Background The COVID‐19 pandemic challenges neurologists in counselling multiple sclerosis (MS) patients with respect to their risk for and by SARS‐CoV‐2 and in guiding disease‐modifying treatment (DMT). The objective was to determine the frequency and distribution of currently known risk factors for COVID‐19 mortality in a MS population. Methods M...
Published in European Journal of Neurology
With interest we read the review article by De Sanctis et al. about 18 patients with Guillain‐Barre syndrome (GBS) associated with the SARS‐CoV‐2 infection (COVID‐19) [1]. Acute, inflammatory, demyelinating polyneuropathy (AIDP) was the most frequent subtype of GBS. We have the following comments and concerns.
Published in European Journal of Neurology
At the time of writing, the number of confirmed COVID‐19 cases in Italy has dropped off to less than 150 cases per day. Now we can finally take a breath and think back on what we have experienced during the last months in our hospital Papa Giovanni XXIII in Bergamo, Lombardy, the epicentre of the Italian pandemic.
Published in European journal of neurology
Published in European journal of neurology
